Therapy Finder – Professional

Treatment is defined as medications, including chemotherapies or targeted drugs, and is exclusive of surgery and radiation in this context.

Genetic mutations can contribute to colorectal cancer growth. This tool uses mutational status to help identify potentially relevant therapies.

The KRAS gene is the most commonly mutated gene in colorectal cancer. The two most common mutations occur at codon 13 (G13) or codon 12 (G12).

Low PTEN expression is often seen in colorectal tumors and can be a contributing cause to tumor growth.

NRAS mutations only occur in a small percentage of colorectal cancer patients.

BRAF is frequently mutated in colorectal cancer with the vast majority of mutations being the ‘V600E’ type.

PIK3CA is frequently mutated in colorectal cancer. The majority of mutations in this gene occur in exon 9 (E542 or E545) or in exon 20 (H1047).

ERCC1 expression levels can be perturbed in colorectal cancer. Information about the expression levels of ERCC1 is useful for making chemotherapy drug decisions.